Zevenbergen Capital Investments’s Adaptive Biotechnologies ADPT Stock Holding History

Zevenbergen Capital Investments’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-698,859	Closed	-$19.6M	–	87
2021 Q4	$19.6M	Sell	698,859 -107,910	-13%	-$3.31M	0.41%	37
2021 Q3	$27.4M	Sell	806,769 -222,345	-22%	-$8.04M	0.52%	39
2021 Q2	$42M	Buy	1,029,114 +4,531	+0.4%	+$176K	0.75%	36
2021 Q1	$41.3M	Buy	1,024,583 +27,334	+3%	+$1.48M	0.78%	32
2020 Q4	$59M	Buy	997,249 +4,610	+0.5%	+$238K	1.03%	30
2020 Q3	$48.3M	Buy	992,639 +215,049	+28%	+$9.04M	0.97%	30
2020 Q2	$37.6M	Buy	777,590 +118,940	+18%	+$4.34M	0.9%	35
2020 Q1	$18.3M	Buy	658,650 +335,990	+104%	+$9.37M	0.69%	31
2019 Q4	$9.65M	Buy	+322,660	New	+$9.27M	0.36%	34

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Zevenbergen Capital Investments's ADPT Position: Q1 2022 in Review

Zevenbergen Capital Investments sold out of Adaptive Biotechnologies (ADPT) in Q1 2022, closing a stake of 698,859 shares — an estimated $19.6M sold.

Zevenbergen Capital Investments first reported a position in ADPT in Q4 2019 and held it in 9 quarters. The position peaked at $59M in Q4 2020. 221 funds tracked by Wall St. Rank hold ADPT as of Q1 2022.

Zevenbergen Capital Investments reported no remaining Adaptive Biotechnologies position as of Q1 2022 after selling out during the quarter.
Zevenbergen Capital Investments sold 698,859 Adaptive Biotechnologies shares in Q1 2022, an estimated $19.6M.
Zevenbergen Capital Investments first reported a position in Adaptive Biotechnologies in Q4 2019 and held it in 9 quarters.
Zevenbergen Capital Investments's Adaptive Biotechnologies position peaked at $59M in Q4 2020.
221 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2022.

Based on Zevenbergen Capital Investments's 13F filing for Q1 2022, filed 12 May 2022.